Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

CVS Health (CVS) Q4 Earnings Top Estimates but Decline Y/Y

By Zacks Investment ResearchStock MarketsFeb 15, 2021 10:40PM ET
www.investing.com/analysis/cvs-health-cvs-q4-earnings-top-estimates-but-decline-yy-200561050
CVS Health (CVS) Q4 Earnings Top Estimates but Decline Y/Y
By Zacks Investment Research   |  Feb 15, 2021 10:40PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

CVS Health (NYSE:CVS) Corporation's CVS fourth-quarter 2020 adjusted earnings per share (EPS) of $1.30 declined 24.9% year over year but exceeded the Zacks Consensus Estimate by 4.8%. The adjusted EPS figure takes into account certain asset amortization costs, acquisition-related integration costs and receipt of fully reserved ACA risk corridor receivable along with other adjustments.

On a reported basis, the company’s earnings of 75 cents per share plunged 43.6% year over year.

Full-year adjusted EPS was $7.50, up 5.9% from the year-ago period. This also surpassed the Zacks Consensus Estimate by 0.9%.

Total revenues in the fourth quarter rose 3.9% year over year to $69.55 billion. The top line also beat the Zacks Consensus Estimate by 1.3%. Full-year 2020 total revenues were $268.71 billion, a 4.6% improvement from 2019. It also exceeded the Zacks Consensus Estimate by a close margin of 0.3%.

Quarter in Detail

Pharmacy Services revenues were down 1.9% to $36.36 billion in the reported quarter. Continued price compression and changes in net new business mix were partially offset by growth in specialty pharmacy and brand inflation.

Total pharmacy claims processed rose 0.7% on a 30-day equivalent basis, attributable to strong net new business.

Revenues from CVS Health’s Retail/LTC were up 6.6% year over year to $24.06 billion. In the quarter, increased prescription volume, COVID-19 diagnostic testing and brand inflation were partially offset by continued reimbursement pressure and the impact of recent generic introductions.

Front store revenues fell 1.6% year over year due to decreased customer traffic and reduced volume in cough and cold product sales primarily as a result of the pandemic. Prescription volume rose 2% on a 30-day equivalent basis on continued adoption of patient care programs. This was partially offset by reduced new therapy prescriptions like lower seasonal flu prescriptions as a result of the pandemic as well as decreased long-term care prescription volume.

Within Health Care Benefits segment, the company registered revenues worth $19.10 billion in the fourth quarter, up 11.4% year over year. The improvement was primarily driven by membership growth in the Health Care Benefits segment's government products and favorable impact of the reinstatement of the HIF (Health Insurer Fee) for 2020 and the receipt of $313 million under the ACA's risk corridor program. This was partially offset by the divestitures of Aetna’s standalone Medicare Part D prescription drug plans and Workers Compensation business, membership declines in the segment’s commercial products and planned COVID- related investments.

Margin

Gross profit improved 9.2% to $27.1 billion. Gross margin expanded 185.3 basis points (bps) to 38.9%. Without considering benefit cost, adjusted operating margin in the quarter under review grew 123 bps to $25.4 billion on a 9.3% rise in adjusted operating profit to $17.67 billion.

2021 Outlook

CVS Health provided its 2021 adjusted EPS and cash flow guidance.

Adjusted EPS is expected in the band of $7.39-$7.55. The Zacks Consensus Estimate for 2021 earnings is pegged at $7.53.

Full-year operating cash flow is expected in the range of $12 billion-$12.50 billion.

Our Take

CVS Health fourth-quarter earnings and revenues surpassed the respective Zacks Consensus Estimate. However, the year-over-year decline in adjusted EPS was concerning. The COVID-19 pandemic affected fourth-quarter revenues in the Pharmacy Services segments as new therapy prescriptions got reduced due to lower provider visits. However, the year-over-year Retail/LTC revenue rise was primarily driven by increased prescription volume and higher front store revenues. Increased guidance amid the pandemic scenario is another positive.

Zacks Rank and Key Picks

CVS Health currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space are Hologic (NASDAQ:HOLX), Inc. HOLX, Abbott Laboratories (NYSE:ABT) ABT and IDEXX Laboratories, Inc. IDXX.

Hologic reported first-quarter fiscal 2021 adjusted EPS of $2.86, beating the Zacks Consensus Estimate by 33.6%. The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Abbott reported fourth-quarter 2020 adjusted EPS of $1.45, which surpassed the Zacks Consensus Estimate by 6.6%. Fourth-quarter worldwide sales of $10.7 billion outpaced the consensus mark by 7.9%. The company currently carries a Zacks Rank #2 (Buy).

IDEXX reported fourth-quarter 2020 adjusted EPS of $2.01, which surpassed the Zacks Consensus Estimate by 40.6%. Revenues of $720.9 million beat the consensus mark by 5.8%. The company currently carries a Zacks Rank #2

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Hologic, Inc. (HOLX): Free Stock Analysis Report

CVS Health Corporation (CVS): Free Stock Analysis Report

Abbott Laboratories (ABT): Free Stock Analysis Report

IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research
CVS Health (CVS) Q4 Earnings Top Estimates but Decline Y/Y
 

Related Articles

CVS Health (CVS) Q4 Earnings Top Estimates but Decline Y/Y

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email